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Abstract
Mammalian sex determination (male versus female) is largely controlled by genes, whereas
sex differentiation (development of reproductive structures) is largely controlled by hor-
mones. Work in the 20th century indicated that female external anatomy was a “default”
pathway of development not requiring steroids, whereas male genital development required
testicular testosterone plus dihydrotestosterone (DHT) made in genital skin according to a
“classic” pathway. Recent work added the description of an alternative “backdoor” pathway
of androgen synthesis discovered in marsupials. Unique “backdoor steroids” are found in
human hyperandrogenic disorders, and genetic disruption of the pathway causes disor-
dered male sexual development, suggesting it plays an essential role. O’Shaughnessy and
colleagues now show that the principal human backdoor androgen is androsterone and pro-
vide strong evidence that it derives from placental progesterone that is metabolized to
androsterone in nontesticular tissues. These studies are essential to understanding human
sexual development and its disorders.
Sexual selection and the importance of sexually dimorphic displays and reproductive struc-
tures were first considered by Darwin and Wallace [1]. We now know that these phenotypes
are largely determined by sex steroids; several sex steroids (estrone, androsterone, progester-
one) were isolated in the 1920s by Leopold Ruzika and Alfred Butenandt, who shared the 1939
Nobel Prize for their discovery. The founder of statistical genetics, Roland Fisher, combined
Darwinian natural selection with Mendelian genetics and proposed that these newly discov-
ered sex hormones acted separately from genes, permitting the distinction between sexual
determination (from genes on sex chromosomes) and sexual differentiation (induced by hor-
mones) [2]. This incisive synthesis remained unproven until Alfred Jost showed that testicular
androgens are required for the differentiation of embryonic Wolffian ducts into male repro-
ductive structures and proposed that the testis also produced a locally acting “Mu¨llerian inhibi-
tory substance” (now called “anti-Mu¨llerian hormone” [AMH]) that was responsible for the
involution of the structures that would otherwise differentiate into a uterus and Fallopian
tubes [3,4]. Two more recent events seem to cement this model. First, after much effort, AMH
was isolated, cloned, and shown to act precisely as Jost had proposed [5,6]. Second, Siiteri and
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Wilson discovered that testosterone secreted by the testis could be 5α-reduced to a more
potent androgen, dihydrotestosterone (DHT), in genital skin [7], leading to the “two-andro-
gen” model of male sexual differentiation, in which testosterone virilizes the Wolffian ducts (to
form the seminal vesicle and ejaculatory ducts) and DHT virilizes the male external genitalia
and urethra [8]. But this model was not strictly proven and required examination of the hor-
mones produced in the testis and genital skin during early fetal development, and for this pur-
pose, conventional laboratory animals proved cumbersome at best.
The “classic” and “backdoor” pathways of androgen synthesis
Clinical studies, studies of human tissues, and studies of conventional laboratory animals had
converged to a classical model of androgen synthesis, both in the testis and in a zone of the pri-
mate adrenal cortex called the zona reticularis [9]. Cholesterol is first converted to pregneno-
lone (Preg) by the cholesterol side-chain cleavage enzyme P450scc (CYP11A1); the 17α-
hydroxylase activity of P450c17 (CYP17A1) then converts Preg to 17OH-Preg, then the 17,20
lyase activity of P450c17 converts 17OH-Preg to dehydroepiandrosterone (DHEA). DHEA is
converted to androstenedione by 3β-hydroxysteroid dehydrogenase type 2 (HSD3B2) in both
the adrenal and testis, but the testis is the major site of the next reaction: conversion of andro-
stenedione to testosterone by 17β-hydroxysteroid dehydrogenase type 3 (HSD17B3). The
resulting testosterone is secreted into the circulation and taken up by genital skin, in which it
is converted to DHT by 5α-reductase type 2 (SRD5A2) (Fig 1).
The pioneering studies of Marilyn Renfree provided an animal model in which the accuracy
of this pathway in the developing male could be tested: the Tammar wallaby [10–12]. Marsu-
pial mammals such as the wallaby differ from more familiar eutherian (placental) mammals in
that gonadal differentiation and sexual development take place after birth, while the newborn
is in the mother’s pouch, where the young are readily accessible for tissue sampling and where
drugs and hormones may be administered without placental intervention. Thus, the wallaby
provided the means for testing the “conventional wisdom” that testosterone is the androgen in
the circulation while DHT is made and acts locally in the genital skin. The wallaby did not
cooperate! Working with Renfree, Wilson, and colleagues discovered that the wallaby pro-
duces DHT by a steroidogenic pathway that had not been seen in eutherian mammals. This
pathway bypasses the usual intermediate steroids DHEA, androstenedione and testosterone.
Instead, 17OH-progesterone is made from 17OH-Preg, then 5α- and 3α- are reduced, sub-
jected to the 17,20 lyase activity of P450c17, then acted on by HSD17B3 to produce 5α-andros-
tane-3α,17β-diol as the circulating product. Similar to the eutherian mammal, the target
tissues perform the final enzymatic transformation: 3α-oxidation to produce DHT [13]. This
novel alternate pathway to DHT thus circumvents the usual steroidal intermediates and has
come to be known as “the backdoor pathway” [14] (Fig 2).
Role of the “backdoor” pathway in human male development
Indirect data supporting the relevance of the backdoor pathway in human physiology are
emerging. Studies measuring steroidal intermediates of the backdoor pathway by liquid chro-
matography coupled with tandem mass spectrometry have indicated that this pathway plays
an important role in human hyperandrogenic disorders such as congenital adrenal hyperplasia
caused by steroid 21-hydroxylase deficiency [15], the polycystic ovary syndrome [16], and
some virilized female newborns with P450 oxidoreductase deficiency [17–19], as well as in the
physiologic male “minipuberty of infancy” [20]. Furthermore, mutations causing disordered
sexual development have been found in the AKR1C2 and AKR1C4 genes that encode the 3α-
reductases that function uniquely in this pathway [21], leading to the conclusion that both the
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“classic” pathway of androgen synthesis and the “backdoor” pathway are needed for normal
human male genital development [22]. Nevertheless, these studies provided only indirect evi-
dence, as androgens in the circulation and tissues were not measured in these fetuses.
The major human “backdoor” androgen is androsterone, derived
from placental progesterone
In the current issue of PLOS Biology, O’Shaughnessy and colleagues addressed the problem
directly by measuring the plasma and tissue concentrations of steroids from the conventional
and backdoor pathways in 42 midgestation human male fetuses [23]. They found that the prin-
cipal circulating androgen is androsterone rather than testosterone and that DHT was below
the limit of detection in blood. As expected, concentrations of androsterone and testosterone
were lower in blood from female fetuses. Rather surprisingly, levels of androsterone and steroi-
dal intermediates specific to the backdoor pathway were found mainly in the placenta, liver,
and adrenal rather than the testis; furthermore, PCR analyses showed similar distributions of
Fig 1. The “conventional” pathway of steroidogenesis. The figure combines adrenal and gonadal pathways. The left-
hand column shows the Δ5 pathway, in which steroids retain the double bond between carbons 5 and 6 in cholesterol’s
B-ring. The StAR protein facilitates import of cholesterol into mitochondrial, in which P450scc (CYP11A1) cleaves off
the side-chain to yield Preg, the first C21 steroid. Δ5 steroids are converted to corresponding Δ4 steroids by 3βHSD2
(HSD3B2) in the adrenal and gonad or by 3βHSD1 in placenta and peripheral tissues. In the absence of P450c17 (in
the adrenal zona glomerulosa), progesterone is 21-hydroxylated by P450c21 (CYP21A2). P450c11AS (Aldo synthase,
CYP11B2) then catalyzes 11-hydroxylase, 18-hydroxylase, and 18-methyl oxidase activities to yield Aldo. In the gonads
and adrenal zona fasciculata, the 17α-hydroxylase activity of P450c17 (CYP17A1) permits synthesis of 17OHP, which
is 11-hydroxylated to cortisol by P450c11β (CYP11B1). The 17,20 lyase activity of P450c17 requires allosteric action of
cytochrome b5 (b5) in the adrenal zona reticularis and testicular Leydig cells, permitting conversion of C21 to C19
steroids. Human P450c17 converts 17OHP to androstenedione with only approximately 2–3% of its activity to convert
17OH-Preg to DHEA so that testosterone synthesis proceeds via DHEA and not via 17OHP; by contrast, rodent and
ungulate P450c17 catalyzes this reaction efficiently. Testicular 17βHSD3 converts DHEA to androstenediol and
androstenedione to testosterone; low levels of adrenal 17βHSD5 (AKR1C3) permit synthesis of small amounts of
testosterone. In the ovary and elsewhere, P450aro (aromatase, CYP19A1) converts C19 androgens to C18 estrogens. In
genital skin, 5α-reductase type 2 (5αRed2, SRD5A2) further activates testosterone to DHT. 17OHP, 17OH-
progesterone; Aldo, aldosterone; C21, 21-carbon; DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone; Preg,
pregnenolone; StAR, steroidogenic acute regulatory protein.
https://doi.org/10.1371/journal.pbio.3000198.g001
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the mRNAs for P450c17, SRD5A2, and AKR1C2/4 in these tissues, suggesting that these tis-
sues were the sites where these steroids were synthesized. Thus, the data are consistent with an
essential role for the backdoor pathway in producing the androgens that virilize the male fetus
but indicate that this androgenesis is distributed among multiple tissues, starting with placen-
tally produced progesterone rather than being confined to testicular Leydig cells, as has been
traditionally envisioned.
Removing the testis from the center of fetal androgen synthesis is a novel, unexpected find-
ing. The work of O’Shaughnessy and colleagues confirms the “two-androgen” model of male
sexual development wherein testosterone is sufficient to stabilize and differentiate the Wolffian
ducts and to promote penile growth, while DHT is needed to virilize the external genitalia. But
the testis is no longer supreme: it is necessary but not sufficient to produce the androgenic ste-
roids that are responsible for male sexual development.
The study was limited to a modest number of fetuses at estimated gestational ages of 11–21
weeks, and concentrations of many of the analytes were near the lower limits of assay detec-
tion. Nevertheless, the specimens used by the authors are difficult to obtain, and the authors
carefully attempted to control for many variables, including fetal sex. Future studies will need
to address the flux of steroids in the various tissues along various steroidogenic steps. The
unexpected results of this study will inspire additional work to unravel the proportions of
androgens derived from the traditional and alternative pathways across gestation and their
Fig 2. The “backdoor” pathway of androgen synthesis. Steroids in the left-hand column (the Δ5 pathway) may be
acted on by either 3βHSD1 or 3βHSD2 to yield the corresponding Δ4 steroids. Following the production of Preg, the
backdoor pathway typically features its conversion to 17OH-Preg, which is then converted to the key intermediary,
17OHP. In the brain (and elsewhere), progesterone may be converted to the neuroactive steroid, allopregnanolone.
17OHP is 5α-reduced by 5αRed1 (SRD5A1) to 5α-pregnan-17α-ol-3,20-dione, which is then 3α-reduced by AKR1C2
or AKR1C4 to yield 17OH-allopregnanolone. P450c17 catalyzes its 17,20 lyase activity very efficiently when 17OH-
allopregnanolone is the substrate, yielding androsterone, which O’Shaughnessy and colleageus show is the principal
androgen in human male fetal circulation. Androsterone may then acted on by testicular 17βHSD3 (or, to a minor
degree, by adrenal 17βHSD5 [AKR1C3]) to yield androstanediol, which may be 3α-oxidized, probably by 17βHSD6
(HSD17B6; also known as RoDH, to yield the most potent androgen, DHT. The work of O’Shaughnessy and
colleagues shows that the human fetal testis instead uses progesterone produced by the placenta to generate the 17OHP
that initiates the backdoor pathway. The identities of all of the enzymes catalyzing the reductive and oxidative 3αHSD
reactions have not been determined unambiguously. 17OHP, 17OH-progesterone; DHT, dihydrotestosterone; Preg,
pregnenolone; RoDH, retinol dehydrogenase.
https://doi.org/10.1371/journal.pbio.3000198.g002
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000198 April 3, 2019 4 / 6
relative contributions to male sexual development in the normal fetus and in disorders of sex
development.
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